The regulatory effects of IFN␥ on CD95 expression and CD95-mediated cell death were investigated in three high-risk pro-B acute lymphoblastic leukemia (ALL) lines that carry the chromosomal translocation t(4;11)(q21;q23). These leukemias are characteristically refractory to conventional chemotherapeutic treatments operating through the induction of apoptosis. However, the mechanisms leading to increased cell survival and resistance to cell death in these leukemias are largely unknown. Interferon-␥ (IFN␥), a potent inhibitor of hematopoiesis, acts in part by upregulating CD95 and sensitizing cells to CD95-induced apoptosis. The t(4;11) lines SEM, RS4;11, and MV4;11 expressed low levels of CD95, but were completely resistant to CD95-mediated death. Addition of IFN␥ markedly upregulated CD95 expression in SEM (8-9-fold), RS4;11 (2-3-fold), and MV4;11 (2-3-fold) lines. However, after treatment with IFN␥, only an 11% increase in sensitivity to CD95-mediated cell death was observed in SEM cells, whereas RS4;11 and MV4;11 cells remained resistant. Cycloheximide, but not actinomycin D or brefeldin A, increased CD95-specific cell death only in IFN␥-treated RS4;11 cells by approximately 12%. Abundant levels of Bcl-2 and Bcl-XL, known to inhibit CD95-signaling in some cells, were present suggesting a possible role for both molecules in the resistance to CD95-mediated cell death. Resistance of the leukemic blasts to CD95-mediated cell death and the failure of IFN␥ to substantially sensitize the CD95-signaling pathway may contribute to the highly malignant phenotype of pro-B ALL with translocation t(4;11).
Introduction
Pro-B acute lymphoblastic leukemia (ALL) is a disease that is prevalent in infants and in early childhood. [1] [2] [3] Chromosomal abnormalities in the ALL-1 gene, also known as MLL, HRX, and HTRX1, [4] [5] [6] [7] on chromosome 11 are frequently involved in childhood ALL. Chromosomal translocation t(4;11)(q21;q23) is present in greater than 60% of infants, 2% of children, and 3-6% of adults with ALL and results in exceedingly poor prognosis. 8 The role of the t(4;11) translocation in the malignant phenotype remains to be elucidated. However, it has been proposed that chimeric proteins from the breakpoint regions on both reciprocal derivative chromosomes are the oncogenes initiating and driving the malignant transformation. 9 The immunophenotype of t(4;11) ALL is that of pro-B cells that often display certain myeloid markers, such as CD13 and CD33. 8 The mixed-lineage phenotype suggests that these leukemias may be generated from pluripotent hematopoietic progenitors that can potentially differentiate into lymphoid or myeloid cells.
CD95, a cell surface receptor belonging to the nerve growth factor/tumor necrosis factor receptor superfamily, is found on Correspondence: SJ Zunino, Chair of Genetics, University of Erlangen-Nü rnberg, Staudtstr. 5, D91058 Erlangen, Germany; Fax: 49 9131 8528526 Received 25 January 1999; accepted 20 April 1999 many cell types. 10, 11 Triggering of the CD95 pathway by CD95 ligand or cross-linking antibody induces apoptosis in sensitive cells. The death-inducing signal complex (DISC) consists of CD95, Fas-associating protein with death domain (FADD), and caspase 8 (FLICE/MACH). 12, 13 Upon recruitment into the DISC, caspase 8 is activated by proteolytic cleavage which then initiates the apoptotic cascade by cleavage of effector caspases, most notably caspase 3.
14-16 Activation of the caspase cascade results in numerous changes in the cell that define apoptosis, such as endonucleolytic cleavage of DNA, proteolytic cleavage of nuclear and cellular proteins, cell membrane blebbing, and production of apoptotic bodies. 17 CD95 is also present on activated T and B lymphocytes and is a means of controlling the immune response to antigen. This receptor system has been implicated in the normal regulation of hematopoiesis and may play a role in the elimination of abnormally developed hematopoietic progenitor cells.
Interferon-␥ (IFN␥) is a pluripotent immunomodulatory cytokine secreted by activated T lymphocytes and natural killer cells. 18 IFN␥ is a well-known inhibitor of hematopoiesis 19, 20 and exerts its suppressive effects in part by upregulating the expression of CD95 and increasing sensitivity to CD95-mediated apoptosis in hematopoietic progenitor cells. 21, 22 This cytokine is also effective in upregulating CD95 on malignant cells, such as breast carcinoma, 23 colon carcinoma, 24 and osteosarcoma. 25 IFN␥ regulates a number of genes other than CD95 that are involved in apoptosis. Recently, Ossina et al 26 showed that IFN␥ induced the transcription of several members of the interleukin-1␤-converting enzyme family, namely caspases 1, 3, 4, 7, 8, and 10. Among the bcl-2 family, IFN␥ induced the expression of bak and mcl-1 mRNAs, but not bax, bcl-XL, bcl-Xs, or bad mRNAs. Transcription of target genes by IFN␥ is mediated primarily by activation and nuclear localization of STAT1 which promotes the transcription of members of the interferon-regulatory factor family. 18 Defective or dysregulated apoptotic pathways during hematopoiesis may play a significant role in the generation of human leukemias. The mechanisms underlying the malignancy of t(4;11) ALL are unknown. The SEM, 27 RS4;11, 28 and MV4;11 29 lines were established from patients with ALL carrying the t(4;11)(q21;q23) chromosomal translocation and these cells provide useful tools to analyze the regulation of apoptosis and their resistance to apoptotic stimuli. We have found that these leukemia-derived cell lines are resistant to CD95-mediated cell death. To gain a more complete understanding of the genetic control mechanisms that lead to the characteristic resistance of these cells to the induction of cell death, we investigated the regulatory effects of the immunosuppressive cytokine IFN␥ on CD95 expression and CD95-mediated death in the t(4;11) pro-B ALL-derived lines.
Materials and methods

Cell culture
SEM, RS4;11, and MV4;11 cell lines were established from patients diagnosed with ALL containing the chromosomal translocation t(4;11)(q21;q23). The SEM line was established by Dr J Greil. The MV4;11 and RS4;11 lines were obtained from Dr R Marschalek, Chair of Genetics, University of Erlangen and are available from American Type Tissue Collection (ATCC, Manassas, VI, USA). The presence of the t(4;11) translocation was confirmed for each cell line by PCR with specific oligonucleotide primers surrounding the translocation breakpoint regions (see below). SEM and RS4;11 cells were maintained in Iscove's modified Dulbecco's medium (GibcoBRL, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (Gibco BRL), 1% penicillin-streptomycin, 0.5% gentamycin, 1% sodium pyruvate, and 1 mm l-glutamine (GibcoBRL). MV4;11 cells, Raji (B lymphoid), and Jurkat (T lymphoid) cells were maintained in RPMI containing the supplements listed above. The cells were analyzed for the presence of mycoplasma contamination using the mycoplasma detection kit from ATCC. All cell lines were negative for mycoplasma.
Antibodies and cytokines
The following antibodies were used for flow cytometric or Western blot analysis: anti-human Bcl-2, clone 124 (Dako Diagnostika, Hamburg, Germany), negative control mouse IgG1 (Dako), phycoerythrin (PE)-conjugated anti-human CD95, clone DX2 (Pharmingen, Hamburg, Germany), PE-conjugated mouse IgG1 (Dako), rabbit anti-Bcl-XL (Transduction Labs, Lexington, KT, USA), affinity-purified rabbit IgG (Dako), anti-actin antibody, clone AC-40 (Sigma, Deisenhofen, Germany), and mouse IgG2a (Dako). For Western blots, horse-radish peroxidase (HRP)-conjugated goat anti-mouse and goat anti-rabbit IgG from Transduction Labs were used at a dilution of 1:1000.
For experiments requiring the induction of CD95-mediated cell death, the cross-linking anti-CD95 IgM, clone CH-11 (Coulter-Immunotech, Krefeld, Germany) and a negative control IgM (Dako) were used at a final concentration of 0.2 g/ml, unless otherwise stated. Recombinant IFN␥ was purchased from R&D Systems (Wiesbaden-Nordenstadt, Germany) and was reconstituted according to manufacturer's recommendation with a solution containing sterile 10 mm acetic acid/0.1% bovine serum albumin (BSA; Carl Roth, Karlsruhe, Germany). Endotoxin level for IFN␥ was less than 0.1 ng/g protein and the specific activity was 10 7 units/mg protein. Untreated cells were incubated with an equal amount of solution containing 10 mm acetic acid/0.1% BSA.
Flow cytometric analysis
Immunofluorescence analysis was performed on a FACSCalibur fluorescence-activated cell sorter (FACS) using CELLQuest software (Becton Dickinson, Mountain View, CA, USA). Surface staining for CD95 was performed using a one-step procedure with PE-conjugated control IgG1 or PE-conjugated anti-CD95, clone DX2. Incubations of the cells with antibody were performed on ice in the dark for 30 min. The cells were washed in phosphate-buffered saline (PBS, Sigma) containing 0.1% BSA and 7 mm sodium azide (Sigma) and then fixed in 1% paraformaldehyde (Sigma) before analysis. All analyses of whole cells were performed using appropriate scatter gates to exclude cellular debris and aggregated cells. Cell death was measured by lysing the cells in a hypotonic solution containing 0.1% sodium citrate, 0.1% Triton X-100, and 50 g/ml propidium iodide (Sigma) and analyzing the fraction of nuclei with sub-diploid DNA content by FACS as previously described. 30 Ten thousand events were collected for each sample analyzed. All statistical analyses were performed with GraphPad software (GraphPad Software, San Diego, CA, USA) and displayed as arithmetic means ± s.e.m. (standard error of the mean). P values were obtained using two-tailed paired ttests with a confidence interval of 95% for evaluation of the significance of differences between treatment groups.
Inhibition of transcription, translation, and protein transport
The transcription inhibitor actinomycin D, the translation inhibitor cycloheximide, and the protein transport inhibitor brefeldin A were purchased from Sigma. SEM, RS4;11, MV4;11, and Jurkat cells were split to a density of 5 × 10 5 /ml and treated with buffer only (untreated) or with IFN␥ at a final concentration of 1000 units/ml. After 48 h, the expression of CD95 was analyzed by FACS and the cells were again split and adjusted to a density of 5 × 10 5 cells/ml in a 24-well plate for treatment with inhibitors. Untreated and IFN␥-treated SEM and RS4;11 cells were incubated with 0.05 g/ml actinomycin D, 1 g/ml cycloheximide, and 1 g/ml brefeldin A in separate wells for 5 h. MV4;11 cells were incubated with 0.0025 g/ml actinomycin D, 0.5 g/ml cycloheximide, and 0.05 g/ml brefeldin A. Jurkat cells were incubated with 0.01 g/ml actinomycin D, 0.5 g/ml cycloheximide, and 0.1 g/ml brefeldin A. Untreated and IFN␥-treated cells were also treated with equivalent amounts of methanol (Sigma) or dimethylsulfoxide (Sigma) to control for sensitivity to the dissolving medium used for each inhibitor. The cells were pretreated with inhibitors for 5 h and then divided equally into two wells. IgM was added to one well as a control and anti-CD95 (clone CH-11) was added to the second well, both at a final concentration of 0.2 g/ml. The cells were incubated for an additional 12 h in the presence of inhibitors and then stained with propidium iodide as described above to measure CD95-induced death.
Western blot analysis
Protein lysates were prepared by vortexing 5 × 10 7 cells per ml of lysis buffer containing 1% Triton X-100 or 1% Igepal (Sigma), 50 mm Tris-Cl, pH 8, 150 mm NaCl, and proteinase inhibitors (Boehringer Mannheim, Mannheim, Germany): 1 g/ml aprotinin, 1 g/ml leupeptin, 1 mm EDTA. Protein concentrations were determined using the BioRad DC protein assay (Munich, Germany). Equal amounts of protein were electrophoresed on 15% SDS-polyacrylamide gels under reducing conditions and electroblotted on to PVDF membrane (Boehringer Mannheim). Ponceau S (Sigma) was used to ensure efficiency of transfer of the proteins before staining. Anti-Bcl-2 and anti-Bcl-XL were used at a concentration of 1 g/ml and 0.2 g/ml, respectively. Blocking and staining of membranes were carried out using 1 × PBS containing 1% nonfat dry milk and 0.1% Tween 20 (Sigma). To control for non-specific binding of each antigen-reactive antibody, a second gel was run in parallel with equal amounts of protein. This second gel was used for staining with a nonspecific negative control antibody, either isotype-matched mouse IgG or rabbit Ig at the same concentrations as the antigen-specific antibody. The presence of equivalent amounts of protein was confirmed by staining with anti-actin antibody at a concentration of 5 g/ml. HRP-conjugated goat anti-mouse or goat anti-rabbit IgG was used as secondary antibody at a dilution of 1:1000. The ECL Western blotting system (Amersham Pharmacia Biotech, Freiburg, Germany) was used for visualization of immunoreactive bands at manufacturer suggested concentrations. Densitometric analysis of protein was performed using WinCam v. 2.1 software (Cybertech, Berlin, Germany).
PCR of genomic DNA
PCR was used to confirm the t(4;11) chromosomal translocation in SEM, RS4;11, and MV4;11. Genomic DNA was isolated by lysing 2.5 × 10 6 cells in 1 × PCR reaction buffer containing 20 mm Tris-HCl, pH 8.4, 50 mm KCl (Gibco BRL) plus 1.5 mm MgCl 2 , 0.5% Igepal, and 0.5% Tween 20. Twenty micrograms of proteinase K was added and the reactions were incubated at 60°C for 1 h and then precipitated with isopropanol (Sigma). PCR reactions consisted of 50 ng genomic DNA, 0.2 m each of 5Ј and 3Ј primer, 1.5 mm MgCl 2 , 0.2 mm each of dTTP, dGTP, dCTP, and dATP, 2.5 units TAQ polymerase (GibcoBRL), and 1 × PCR reaction buffer. Sequences specific for the translocation breakpoint in the ALL-1 gene for each cell line were kindly provided by Dr Rolf Marschalek (Chair of Genetics, University of Erlangen). 31 The following oligonucleotide primer sequences were used: for SEM, oligonucleotides I27.3 (5Ј GGAGATAACTGTAG-GTGACC 3Ј) and 11.5 (5Ј GATTCCTAAGCCTCCCATC 3Ј); for RS4;11, oligonucleotides I27.51 (5Ј GCACCTCCAAGCA-TGCCAC 3Ј) and I9.33 (5Ј CATTTGCATTATTATCTGTTGCA 3Ј); for MV4;11, oligonucleotides AF4I.31 (5Ј GTTCTA-GTTTACCTCTTAGTGAG 3Ј) and I9.52 (5Ј CCTAGGCTA-GAACATGTGG 3Ј). Standard conditions for amplification were 94°C, 30 s, 58°C, 30 s, and 72°C, 90 s for 35 cycles. 
Results
The t(4;11) ALL lines express low levels of CD95 and are resistant to CD95-induced cell death
The expression of CD95 on the surface of SEM, RS4;11, and MV4;11 cells was measured by labeling the cells with PE-conjugated control antibody or PE-conjugated anti-CD95 and analyzing mean fluorescence intensity by FACS. CD95 was expressed at low levels on the cell surface of all three t(4;11) ALL lines (Figure 1a) . In contrast, Jurkat T cells expressed 10-fold or higher amounts of CD95 on their cell surface when compared to the t(4;11) leukemia lines. Owen-Schaub et al 32 have shown that the amount of CD95 surface protein present on a cell is not a reliable predictor of a functional CD95-signaling pathway. Therefore, we investigated whether the t(4;11) cells were sensitive to CD95-induced cell death by incubating the cells with 0.2 g/ml of a non-specific IgM or the anti-CD95 cross-linking antibody (IgM, clone CH-11) for 18-20 h. Clone CH-11 has been shown to mimic the effects of CD95 ligand and induces apoptosis in CD95-sensitive cells. As a control for CD95-mediated cell death, we included The t(4;11) ALL lines express CD95, but are resistant to CD95-mediated cell death. (a) The t(4;11) ALL lines and Jurkat T cells were stained with either PE-conjugated mouse IgG1 as a control (white) or PE-conjugated anti-CD95 (gray) and analyzed by flow cytometry. Histograms represent approximately 7-8000 events gated on light scatter parameters to exclude debris and cell aggregates. (b) The cells were incubated with either mouse IgM as a control (white bar) or mouse anti-human CD95, clone CH-11 (hatched) to determine sensitivity to CD95-dependent cell death. After 18 h, the cells were lysed in hypotonic solution of propidium iodide and analyzed by FACS as previously described. 30 Jurkat T cells were used as a positive control for CD95-mediated death. The data presented represent the arithmetic mean of the percent cell death ± s.e.m. (standard error of the mean) from three experiments.
CD95-sensitive Jurkat T cells in all analyses. After ligation with the cross-linking antibody, approximately 50% CD95-specific death was observed in Jurkat cells compared to the IgMtreated control cells (P Ͻ 0.001; Figure 1b) . However, no significant difference in cell death was observed in the three t(4;11) leukemia lines after treatment with IgM control or anti-CD95 antibodies, indicating the t(4;11) ALL cells were completely resistant to CD95 signaling (Figure 1b) .
IFN␥ markedly increases expression of CD95 on the cell surface of t(4;11) pro-B ALL cells
IFN␥ is a known inhibitor of hematopoietic cell growth. 19, 20 This inhibitory activity is mediated in part by the ability of IFN␥ to upregulate the expression of CD95 in hematopoietic progenitor cells with concomitant increase in CD95-mediated apoptosis. 21, 22 Furthermore, IFN␥ has been reported to upregulate CD95 on the cell surface of other types of cells and increase the sensitivity of these cells as well to CD95-mediated apoptosis.
23-25 Therefore, we investigated whether it was possible to upregulate CD95 in our t(4;11) ALL lines by treatment with IFN␥ and to subsequently increase the sensitivity of these leukemia cells to CD95-induced death.
After a 48 h treatment with and without IFN␥, the cells were analyzed by FACS for cell surface expression of CD95. A significant increase in expression of CD95 protein was observed in all three t(4;11) ALL lines treated with IFN␥ compared to the untreated cells (Figure 2) . FACS analysis showed an approximate 8-9-fold increase for SEM cells and 2-3-fold increases for both RS4;11 and MV4;11 cells in CD95 expression after treatment with 1000 units/ml IFN␥ compared to untreated cells. Jurkat T cells displayed no change in CD95 protein expression in the presence or absence of IFN␥.
To determine the sensitivity of the t(4;11) leukemias to IFN␥-induced upregulation of CD95 protein, time course and dose response analyses were performed. The time course analysis indicated that the expression of CD95 protein was maximal at 48-72 h in the t(4;11) leukemia lines ( Figure 3 ) and was not increased above this level after further incubations with IFN␥ for 4, 6 and 8 days (data not shown). Dose response determinations with concentrations of IFN␥ from 20 to 5000 units/ml revealed that a statistically significant increase in cell surface expression of CD95 was observed in SEM (P Ͻ 0.01) and RS4;11 (P Ͻ 0.002) at a dose of 20 units IFN␥/ml (Figure 3 ) by 24 h after treatment, indicating that these cells were very sensitive to the CD95-inductive effects of IFN␥. MV4;11 showed a significant increase in CD95 expression at a dose of 100 units IFN␥/ml (P Ͻ 0.02). Furthermore, the level of CD95 expression did not change significantly in the t(4;11) ALL lines with higher doses of IFN␥. CD95 expression remained relatively constant in Jurkat cells regardless of the dose of IFN␥.
Treatment with IFN␥ does little to sensitize the t(4;11) ALL cells to CD95-mediated cell death
The three t(4;11) ALL lines responded to IFN␥ by substantially upregulating expression of CD95 protein. To determine whether the treatment of these leukemia cells with IFN␥ would also lead to an increase in sensitivity to CD95-mediated cell death, we analyzed the induction of cell death after overnight ligation with cross-linking anti-CD95 antibody. The CD95-sensitive Jurkat T cell line was again used as a positive control for CD95-induced death. Cells were cultured in the presence or absence of IFN␥ for 48 h and analyzed by FACS for upregulation of CD95. After ensuring that CD95 was upregulated by the IFN␥ treatment, untreated and IFN␥-treated cells were incubated with either non-specific IgM or anti-CD95 (clone CH-11) antibody for approximately 18 h. Although CD95 levels were markedly increased on the cell surface of the t(4;11) ALL cells by IFN␥, only SEM cells showed a weak, but statistically significant increase in sensitivity to CD95-signaling after IFN␥ treatment. Cell death in the IFN␥-treated SEM population increased by approximately 11% from 16.4 ± 1.9% to 27.5 ± 3.8% (± standard error; P Ͻ 0.01) after ligation with anti-CD95 antibody compared to control IgM (Figure 4 ). However, RS4;11 and MV4;11 cells remained resistant to CD95-mediated cell death after treatment with IFN␥. As expected, approximately 45% CD95-specific death was observed in Jurkat T cells after incubation with cross-linking antibody, and pretreatment of Jurkat T cells with IFN␥ did not change the percentage of death observed (Figure 4) .
Cycloheximide increased the sensitivity of RS4;11, but not SEM or MV4;11, to CD95-dependent cell death
The transcriptional inhibitor actinomycin D, the translational inhibitor cycloheximide, and the inhibitor of protein transport brefeldin A were used to analyze whether de novo transcription, de novo protein synthesis, or protein transport through the Golgi was required for the CD95-resistant phenotype of the t(4;11) ALL lines. After a 48 h incubation with buffer or IFN␥, actinomycin D, cycloheximide, and brefeldin A were added separately to untreated and IFN␥-treated cells for 5 h. The cells were then incubated for an additional 12 h with either IgM control antibody or anti-CD95 IgM in the continued presence of the inhibitors. We found that longer exposure of the cells to the inhibitors or any increase in the concentration of inhibitors produced a higher level of inhibitor-induced death, but did not increase the level of CD95-specific death. Furthermore, MV4;11 and Jurkat cells displayed greater sensitivity to the cytotoxic action of the inhibitors than did SEM and RS4;11 cells. Therefore, the concentrations of each inhibitor used in these experiments were adjusted for each line to reduce inhibitor-mediated death. Under these conditions, SEM and MV4;11 cells were not sen-
Figure 3
CD95 expression is induced by low doses of IFN␥ in t(4;11) ALL: dose response and time course of induction. The t(4;11) ALL lines and Jurkat T cells were incubated with 0 (), 20 ( ), 100 ( ), 1000 ( ), and 5000 ( ) units/ml of IFN␥ over three days to determine the sensitivity of these cells to the induction of CD95. Cells were harvested after 24, 48, and 72 h of incubation and analyzed for CD95 expression by staining with PE-conjugated anti-CD95 as described above. PE-conjugated mouse IgG1 was included for each population as a background control (data not shown) and all groups showed equivalent non-specific staining profiles as shown in Figures 1a and 2 . The data presented represent the arithmetic mean of the relative fluorescence intensity ± s.e.m. from four separate experiments. Numbers were obtained from FACS analysis of cells gated on light scatter parameters to exclude debris and cell aggregates. sitized further to CD95-mediated death by treatment with actinomycin D, cycloheximide, or brefeldin A ( Figure 5 ). IFN␥-treated SEM cells continued to display an approximately 11% increase in CD95-dependent death in both the control cell population and in the presence of cycloheximide. However, both actinomycin D and brefeldin A appeared to abrogate CD95-sensitivity in SEM cells. Cycloheximide was able to weakly enhance CD95-mediated death only in RS4;11 cells pretreated with IFN␥ ( Figure 5 ). The increase in CD95-specific cell death observed for RS4;11 cells in the presence of both IFN␥ and cycloheximide was 12.4% (8.6 ± 0.7% to 21 ± 2.3%) with P = 0.0374, indicating the difference was statistically significant. Treatment of RS4;11 cells with a combination of IFN␥ and actinomycin D or brefeldin A did not produce a statistically significant difference in cell death after ligation with anti-CD95 antibody. Jurkat cells, however, showed a substantial increase in CD95-dependent death after treatment with all three inhibitors ( Figure 5 ). CD95-mediated death in Jurkat cells increased above background death from approximately 40% in control cells to approximately 70% after treatment with actinomycin D, 50% after treatment with brefeldin A, and 80% after treatment with cycloheximide.
Expression of Bcl-2 and Bcl-XL after IFN␥ treatment
Bcl-2 and Bcl-XL have been shown by several investigators to be inhibitors of the CD95-signaling pathway when overexpressed in certain cell types. [33] [34] [35] Abundant levels of Bcl-2 have been previously reported in SEM, RS4;11, and MV4;11, as well as primary B-lineage ALLs. [36] [37] [38] Since SEM cells showed an increase in sensitivity to CD95-mediated death Expression of Bcl-2 protein in t(4;11) ALL lines with and without IFN␥ treatment. Cells were left untreated (lane 1) or treated with 1000 units/ml of IFN␥ (lane 2) for 48 h and then harvested for analysis of Bcl-2 protein expression. Fifty to 60 g of total protein per lane were electrophoresed in 15% SDS-PAGE gels under reducing conditions and blotted on to PVDF membranes. A second gel was run with equivalent amounts of loaded protein for staining with isotypematched mouse antibody as a control for non-specific binding. Antiactin antibody was used as a control for equal loading of protein on the gels and efficient transfer of proteins on to the membrane. Densitometric analysis was performed with WinCam v.2.1 software.
after IFN␥ treatment, we analyzed whether the levels of Bcl-2 or Bcl-XL were reduced in these cells in response to IFN␥ treatment. We examined the expression levels of both Bcl-2 and Bcl-XL by Western blot in the t(4;11) leukemia lines that had been untreated or treated with IFN␥ for 48 h. Greater than 14-fold higher expression of Bcl-2 was found in the t(4;11) ALL cells compared to Raji B-lymphoblastoid cells and eightfold higher expression compared to Jurkat T cells ( Figure 6 ). However, Bcl-2 protein was expressed at similar levels in all three t(4;11) lines and no change in expression was observed by Western blot between untreated and IFN␥-treated cells.
Expression of Bcl-XL was more variable between untreated and IFN␥-treated SEM, RS4;11, and MV4;11 cells. The results presented in Figure 7 are representative of three experiments. Both untreated SEM and RS4;11 expressed similar amounts of Bcl-XL. However, 1.4 to 2.4-fold increases in Bcl-XL protein were observed in RS4;11 cells after 48 h treatments with IFN␥ compared to the untreated population ( Figure 7 ). The expression of Bcl-XL was generally lower in MV4;11 cells than in the other lines. Furthermore, after 48 h treatment with IFN␥, MV4;11 showed 1.3-1.8-fold decreases in Bcl-XL compared to the untreated population. No changes in Bcl-XL levels were IFN␥ regulates expression of Bcl-XL in RS4;11 and MV4;11 cells. Analysis of Bcl-XL protein expression was performed as described in Figure 6 . A second gel with equivalent amounts of loaded protein was stained with rabbit IgG as a control for non-specific binding. Anti-actin antibody was used as a control as described. Densitometric analysis was performed with WinCam v.2.1 software. observed in either Raji B cells or Jurkat T cells between untreated and IFN␥-treated populations.
Discussion
Immune surveillance systems mediated by cytotoxic lymphocytes eliminate aberrant or cancerous cells through either the granzyme-pathway or CD95-CD95 ligand interactions. 39 Interaction of CD95 with its ligand normally triggers the apoptotic pathway in CD95-sensitive target cells. IFN␥ is a pluripotent cytokine normally produced by activated cytotoxic T lymphocytes and NK lymphocytes. 18 Among its many immunological regulatory functions, IFN␥ has been shown to upregulate the expression of CD95 in numerous cell types, including hematopoietic progenitor cells, causing them to be more sensitive to CD95-mediated cell death. [21] [22] [23] [24] [25] This effect has been implicated in the normal regulation of hematopoiesis and has been proposed to play a role in the elimination of abnormally developed hematopoietic progenitor cells. We observed a low level of CD95 on the cell surface of the t(4;11) ALL lines and complete resistance to cell death mediated by CD95. Because IFN␥ has been shown to increase CD95 expression and sensitize hematopoietic and other cells to CD95-signaling, we expected to observe an increase in CD95-sensitivity in our t(4;11) lines after IFN␥ treatment. Indeed, a marked increase in CD95 protein expression was produced by treatment with IFN␥ in all three lines. However, surprisingly, only SEM cells responded to IFN␥ with a modest (11%) albeit statistically significant increase in CD95-mediated death, whereas RS4;11 and MV4;11 cells remained insensitive. Recently, it was shown that IFN␥ can induce the transcription of a number of other apoptosis-related gene products including caspase 3, caspase 8, the Bcl-2 family members bak and mcl-1, but not bax, bcl-x, or bad. 26 The degree to which SEM cells increased the expression of CD95 after IFN␥ treatment indicated that these cells were generally more responsive to the inductive effects of IFN␥. SEM cells showed an 8-9-fold increase in CD95 protein expression compared to 2-3-fold for both RS4;11 and MV4;11 cells. The increase in CD95-mediated death in SEM cells after IFN␥ treatment may reflect a greater sensitivity to IFN␥-mediated induction of more than one key apoptosis-related gene.
Treatment of cells with inhibitors of transcription, translation, and protein transport have been shown to sensitize many CD95-resistant cells to CD95-mediated apoptosis by inhibiting the de novo synthesis of labile proteins that interfere with CD95-signaling. 40 We used actinomycin D, cycloheximide, and brefeldin A as inhibitors of transcription, translation, and protein transport, respectively, to determine if the t(4;11) cells required de novo protein synthesis or transport to maintain their CD95-resistant phenotype. Jurkat T cells were exquisitely sensitive to the inhibitory action of all three inhibitors and showed a substantial increase in CD95-specific cell death after these treatments. From these data, it appears that continuous synthesis of a labile gene product partially blocks the CD95-dependent apoptotic pathway in Jurkat cells and inhibition of de novo synthesis in these cells allows a substantial increase in sensitivity to CD95-signaling. Inhibition of de novo synthesis of labile products appeared to have little effect on the CD95-resistant phenotype in the t(4;11) ALL lines. We found only a weak enhancement in CD95-dependent death in RS4;11 cells treated with IFN␥ and the inhibitor cycloheximide, but additional effects were not observed in SEM or MV4;11 cells. However, analysis of these data is complicated by the sensitivity of the t(4;11) lines to the cytotoxic action of the inhibitors. Previous analysis by others has revealed that resistance to CD95-signaling is common to B-lineage ALL. 41 Beltinger et al 42 have indicated that mutations in the CD95 gene are not common in these leukemias and do not appear to be a factor in generating the resistance to CD95-mediated death. Further experimentation will be required to elucidate the mechanism that protects these leukemias from CD95-dependent death.
Members of the Bcl-2 family have been implicated as protectors against CD95-mediated apoptosis in some cells. Scaffidi et al 35 identified two CD95 signaling pathways that either were not blocked (type I cells) or were blocked (type II cells) by overexpression of Bcl-2 or Bcl-XL. The presence of abundant levels of Bcl-2 and Bcl-XL in the t(4;11) ALL cells implicates a possible role for Bcl-2 family members in the generation of a CD95-resistant phenotype. We and others 36,37 have observed a relatively high level of expression of Bcl-2 in the three t(4;11) ALL lines. Coustan-Smith et al 38 have also reported Bcl-2 expression in B-lineage ALL is in general markedly higher than normal lymphoid progenitors. The presence of high levels of Bcl-2 and/or Bcl-XL could conceivably impair the normal immune response against the leukemia by impairing the CD95-signaling pathway. Although SEM cells responded to IFN␥ with a small increase in sensitivity to CD95-mediated death, we were unable to observe a change in the expression level of Bcl-2 by Western blot. However, it has recently been suggested that the phosphorylation state rather than the relative levels of Bcl-2 may be more important for the protective function of this protein. 43 We are currently investigating the role of IFN␥-regulated induction of apoptosis-related genes and the possible protective roles Bcl-2 and Bcl-XL may play in generating CD95-resistance in the t(4;11) ALL lines.
The t(4;11)(q21;q23) pro-B ALL is a highly aggressive leukemia found most frequently in infants. Little is known about the mechanisms that regulate cell survival and apoptosis in these leukemias and it is still unclear what role the translocationgenerated oncogenes may play in generating this malignancy. The studies presented here were performed exclusively with t(4;11) lines that were established by long-term culture. Therefore, to exclude the possibility that these lines may not exactly reflect the phenotype or genotype of primary leukemic cells, these studies must naturally be extended to primary patient material. However, the SEM, RS4;11, and MV4;11 lines provide useful tools to analyze regulatory processes involved in cell growth and cell death and responses to immunomodulatory factors. These leukemia lines are highly resistant to CD95-mediated cell death and the immune modulator IFN␥ is not particularly effective in sensitizing these cells to CD95 signaling. The results presented in this study do suggest that t(4;11) leukemias may have developed an effective system to by-pass CD95-CD95L interactions promoted by activated, IFN␥-producing cytotoxic lymphocytes. Further understanding of CD95-resistance in these cells may lead to additional insights into the pathology of pro-B t(4;11) ALL and may suggest novel, more effective strategies for treatment of this disease.
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